Contact this trialFirst, we need to learn more about you.
Sodium-glucose cotransporter 2 (SGLT2) Inhibitor
Empagliflozin +2 More for Type 2 Diabetes
Recruiting1 awardPhase 3
Detroit, Michigan
This trial will be conducted in 2 parts: a run-in phase and a treatment phase. The run-in phase is designed to ensure that patients are able to take the study drugs as described in the protocol. After the run-in phase, there will be a 26-week treatment phase, during which patients will be randomly assigned to receive one of the 3 study treatments: empagliflozin 10 mg, empagliflozin 25 mg, or linagliptin 5 mg. Following the treatment phase, there will be a 26-week safety extension phase, during which patients will continue on the same treatment they were receiving
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.